Baccarani, Michele

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,547

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 947

Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study

Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., et al. (2007) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 370

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Perrone, G., Hideshima, T., Ikeda, H., Okawa, Y., Calabrese, E., Gorgun, G., Santo, L., Cirstea, D., Raje, N., Chauhan, D., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsVitamin C and Antioxidants Research

Cited by 109

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Soverini, S., Bavaro, L., De Benedittis, C., Martelli, M., Iurlo, A., Orofino, N., Sica, S., Sorà, F., Lunghi, F., Ciceri, F., et al. (2020) · Blood

Chronic Myeloid Leukemia TreatmentsLung Cancer Treatments and Mutations

Cited by 100

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., Guilhot, F., Heibl, S., Hehlmann, R., Faber, E., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 96

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 91

BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

Soverini, S., Martelli, M., Bavaro, L., De Benedittis, C., Sica, S., Sorà, F., Iurlo, A., Bonifacio, M., Pregno, P., Galimberti, S., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 29

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Lauseker, M., Bachl, K., Turkina, A., Faber, E., Prejzner, W., Olsson‐Strömberg, U., Baccarani, M., Lomaia, E., Zackova, D., Ossenkoppele, G., et al. (2019) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 28

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network

Specchia, G., Pregno, P., Breccia, M., Castagnetti, F., Monagheddu, C., Bonifacio, M., Tiribelli, M., Stagno, F., Caocci, G., Martino, B., et al. (2021) · Frontiers in Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21